4//SEC Filing
Harsh Michael 4
Accession 0001209191-19-060087
CIK 0001681682other
Filed
Dec 10, 7:00 PM ET
Accepted
Dec 11, 5:49 PM ET
Size
10.3 KB
Accession
0001209191-19-060087
Insider Transaction Report
Form 4
Harsh Michael
Director
Transactions
- Award
Series A Convertible Preferred Stock
2019-12-11$1143.68/sh+9.618$11,000→ 9.618 totalExercise: $0.87From: 2019-12-11→ Common Stock (11,056 underlying) - Award
Stock option (right to buy)
2019-12-11+89,922→ 89,922 totalExercise: $0.90Exp: 2029-12-11→ Common Stock (89,922 underlying) - Award
Warrants
2019-12-11+11,056→ 11,056 totalExercise: $0.87From: 2019-12-11Exp: 2024-12-11→ Common Stock (11,056 underlying)
Footnotes (4)
- [F1]These options vest and become exercisable in three equal annual installments beginning on the one year anniversary of the grant date.
- [F2]The Series A preferred stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A preferred stock is convertible into common stock at a price per share of $0.87.
- [F3]The Series A preferred stock has no expiration date.
- [F4]The Warrants were issued for no additional consideration in connection with the purchase of the Series A preferred stock.
Documents
Issuer
ENDRA Life Sciences Inc.
CIK 0001681682
Entity typeother
Related Parties
1- filerCIK 0001706155
Filing Metadata
- Form type
- 4
- Filed
- Dec 10, 7:00 PM ET
- Accepted
- Dec 11, 5:49 PM ET
- Size
- 10.3 KB